Company Profile LogoActinium Pharmaceuticals

Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.

Edit IconSuggest an Edit
Health Care
Health Diagnostics
Clinical Trials
Pharmaceutical
Medical
Biotechnology

    Unlock insights on Actinium Pharmaceuticals and 2M+ companies now!

    About Actinium Pharmaceuticals

    Actinium Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies. The company’s principal product candidates include Actimab-A, a Phase I/II clinical trial monoclonal antibody for the treatment of acute myeloid leukemia in elderly patients; and Iomab-B that has completed a Phase I/II design trial used to condition the bone marrow of patients by destroying blood

    Company Highlights
    Year Founded

    2000

    icon-altEmployees

    63

    Location (HQ)

    USA

    Since Last Funding

    4 years 2 months

    Monthly Website Visitors

    12.0K

    icon-altTotal Investment Amt

    $100M

    Last Funding Round

    Post Ipo Equity

    icon-altMoM Headcount Growth

    1.61%

    icon-altYoY Headcount Growth

    1.61%

    Key Metrics

    Senior Hires

    NameLinkedin ProfilePositionDate Joined
    John Doehttps://www.linkedin.com/in/johndoeCEOCEO
    Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
    John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
    Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
    Get API access to complete private company database with growth metrics from 15 sources

    Similar Companies

    Health Care

    Medical

    Biotechnology

    Biotechnology Research

    Pharmaceutical

    Clinical Trials

    Health Diagnostics